nach oben

CNS Drugs

Erschienen in:

01.02.2003 | Review Article

Compliance with Stimulants for Attention-Deficit/Hyperactivity Disorder

Issues and Approaches for Improvement

verfasst von: Dr James Swanson

Erschienen in: CNS Drugs | Ausgabe 2/2003

Einloggen, um Zugang zu erhalten

Abstract

Attention-deficit/hyperactivity disorder (ADHD) affects approximately 8–10% of school-aged children in the US and for many individuals persists into adolescence and adulthood. Both pharmacological and nonpharmacological (behavioural) therapies are used to treat individuals with ADHD. Treatment with stimulant medications, which include methylphenidate and amphetamine, typically requires multiple daily doses to maintain efficacy. The frequency of treatment, coupled with the importance of timing of doses and the long-term nature of treatment, make noncompliance a particular issue in the treatment of ADHD. Studies report noncompliance rates of 20–65% with stimulant treatment, although there are only limited published studies and these show considerable individual variation. Noncompliance can arise through inadequate supervision of those receiving medication, leading to delayed or missed doses, or through the reluctance of individuals to take medication, which is influenced by a number of factors (e.g. social attitudes, pressures or worries surrounding medication use and the inconvenience of multiple daily doses). Two approaches are likely to increase compliance with stimulant treatment: effective once-daily formulations of medication and improved treatment information. The development of effective once-daily formulations for stimulant treatments removes the need for multiple daily doses, with the associated problems of ensuring adequate treatment supervision and personal privacy. Improved provision of education and information for individuals with ADHD, as well as their families and teachers, should help them address the issues surrounding stimulant medication and allow full participation in the treatment process. Together, these strategies should improve treatment compliance for individuals with ADHD.

Use of tradenames is for product identification only and does not imply endorsement.

US Department of Health and Human Services. Mental health: a report of the Surgeon General. Rockville (MD): US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, National Institutes of Health, National Institutes of Mental Health, 1999

American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

Weiss G, Hectman L, Milroy T, et al. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Adolesc Psychiatry 1985; 24: 211–20CrossRef

American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics 2000; 105: 1158–70CrossRef

Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001; 107(3): E43PubMedCrossRef

Swanson JM, Sergeant JA, Taylor E, et al. Attention-deficit/ hyperactivity disorder and hyperkinetic disorder. Lancet 1998; 351: 429–33PubMedCrossRef

Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 2nd ed. New York: The Guilford Press, 1998

Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 1997; 36(8): 1036–45PubMedCrossRef

MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073–86CrossRef

10.

Swanson JM, McBurnett K, Wigal T, et al. The effect of stimulant medication on ADD children: a “review of reviews”. Except Child 1993; 60: 154–62

11.

Swanson JM, McBurnett K, Christian DL, et al. Stimulant medications and the treatment of children with ADHD. Adv Clin Child Psychol 1995; 17: 265–322

12.

American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 2001; 108: 1033–44CrossRef

13.

Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention deficit hyperactivity disorder. Rockville (MD): McMaster University, 1999

14.

Pelham WE, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychology 1998; 27(2): 190–205CrossRef

15.

Greenhill LL, Swanson JM, Vitello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 180–7PubMedCrossRef

16.

Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001; 40(2): 168–79PubMedCrossRef

17.

Swanson JM, Lerner M, Williams L. Letter to the editor: more frequent diagnosis of attention deficit-hyperactivity disorder [letter]. New Engl J Med 1995; 333(14): 944PubMedCrossRef

18.

Class S. Too much attention paid to ADHD? [online]. Available from URL: http://www.inpharm.com/inlelligence/ims020301.html [Accessed 2002 Nov 5]

19.

Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41Suppl. 2: 26S–49SPubMed

20.

Woodworth T. DEA congressional testimony: statement before the Committee on Education and the Workforce: Subcommittee on Early Childhood, Youth and Families [online]. Available from URL: http://www.dea.gov/pubs/cngrtest/ct051600.htm [Accessed 2000 May 16]

21.

Tomkins CP, Soldin SJ, MacLeod SM, et al. Analysis of pemoline in serum by high performance liquid chromatography: clinical application to optimize treatment of hyperactive children. Ther Drug Monit 1980; 2: 255–60PubMedCrossRef

22.

Collier CP, Soldin SJ, Swanson JM, et al. Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity. Clin Pharmacokinet 1985; 10: 269–78PubMedCrossRef

23.

Pelham WE, Sturges J, Hoza J, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987; 80: 491–501PubMed

24.

Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990; 86: 226–37PubMed

25.

Pelham WE, Swanson JM, Furman MB, et al. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 1995; 34(11): 1504–13PubMedCrossRef

26.

Sheveli M, Schreiber R. Pemoline-associated hepatic failure: a critical analysis of the literature. Pediatr Neurol 1997; 16: 14–6CrossRef

27.

Swanson JM, Kinsbourne M, Roberts W, et al. A time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 1978; 61:21–9PubMed

28.

Chan YM, Swanson JM, Soldin SS, et al. Methylphenidate HC1 (Ritalin) given with or before breakfast. Part II: effects on the plasma concentration of methylphenidate and ritalinic acid. Pediatrics 1983; 72: 56–9

29.

Swanson JM, Sandman CA, Deutsch C, et al. Methylphenidate (Ritalin) given with or before breakfast. Part I: behavioral, cognitive, and electrophysiological effects. Pediatrics 1983; 72: 49–55

30.

Grcevich S. SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs 2001; 10: 2003–11PubMedCrossRef

31.

Dulcan MK. Using psychostimulants to treat behavioral disorders of children and adolescents. J Child Adolesc Psychopharmacol 1990; 1:7–20PubMedCrossRef

32.

Adesman AR, Morgan AM. Management of stimulant medications in children with attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999; 46(5): 945–63, vii-viiiPubMedCrossRef

33.

Szymanski ML, Zolotor A. Attention-deficit/hyperactivity disorder: management. Am Fam Physician 2001; 34: 1355–62

34.

Elia J, Rapoport JL. Ritalin versus dextroamphetamine in ADHD: both should be tried. In: Greenhill LL, Osman BB, editors. Ritalin: theory and patient management. New York: Mary Ann Liebert, 1991: 69–74

35.

Efron D, Jarman FC, Barker MJ. “Side effects” of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind crossover trial. Pediatrics 1997; 100(4): 662–6PubMedCrossRef

36.

Hack S, Chow B. Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 2001; 11(1): 59–67PubMedCrossRef

37.

Kauffman RE, Smith-Wright D, Reese CA, et al. Medication compliance in hyperactive children. Pediatr Pharmacol (New York) 1981; 1(3): 231–7

38.

Firestone P. Factors associated with children’s adherence to stimulant medication. Am J Orthopsychiatry 1982; 52(3): 447–57PubMedCrossRef

39.

Sleator EK, Ullman RK, von Neumann A. How do hyperactive children feel about taking stimulants and will they tell the doctor? Clin Pediatr 1982; 21: 474–9CrossRef

40.

Brown RT, Borden KA, Clingerman SR. Adherence to methylphenidate therapy in a pediatric population: a preliminary investigation. Psychopharmacol Bull 1985; 21(1): 28–36PubMed

41.

Brown RT, Borden KA, Wynne ME, et al. Compliance with pharmacological and cognitive treatments for attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1987; 26(4): 521–6PubMedCrossRef

42.

Brown RT, Borden KA, Wynne ME, et al. Patterns of compliance in a treatment program for children with attention deficit disorder. J Compliance Health Care 1988; 3: 23–9

43.

Johnston C, Fine S. Methods of evaluating methylphenidate in children with attention deficit hyperactivity disorder: acceptability, satisfaction, and compliance. J Pediatr Psychol 1993; 18(6): 717–30PubMedCrossRef

44.

Weiss M, Jain U, Garland J. Clinical suggestions for management of stimulant treatment in adolescents. Can J Psychiatry 2000; 45: 717–23PubMed

45.

Efron D, Jarman FC, Barker MJ. Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. J Paediatr Child Health 1998; 34(3): 288–92PubMedCrossRef

46.

Safer DJ, Krager JM. The increased rate of stimulant therapy for hyperactive/inattentive students in secondary schools. Pediatrics 1994; 94: 462–4PubMed

47.

Reid R, Hertzog M, Snyder M. Educating every teacher, every year: the public schools and parents of children with ADHD. Semin Speech Lang 1996; 17(1): 73–90PubMedCrossRef

48.

Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24(2): 302–16PubMedCrossRef

49.

Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002; 95(1): 68–71PubMed

50.

Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23(8): 1296–310PubMedCrossRef

51.

Fitzpatrick PA, Klorman R, Brumaghim JT, et al. Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1992; 31(2): 226–34PubMedCrossRef

52.

Greenhill LL, Osman BA, editors. Ritalin: theory and patient management. New York: Mary Ann Liebert, 1999

53.

Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 1999; 66: 295–305PubMedCrossRef

54.

Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD: proof of concept and proof of product studies. Arch Gen Psychiatry. In press

55.

Swanson J, Gupta S, Williams L, et al. Efficacy of anew pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 2002; 41:1306–14PubMedCrossRef

56.

Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta™ methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107(6): E105PubMedCrossRef

57.

Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108(4): 883–92PubMedCrossRef

58.

Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998; 34: 47–53PubMed

59.

Greenhill LL. Once-daily methylphenidate treatment for children with ADHD: the Concerta® Study Group [poster presentation]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2001 Oct 23–28; Honolulu

60.

McDaniel D, Greenhill LL. Once-daily methylphenidate formulation for ADHD evaluated in the community [poster presentation]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2001 Oct 23–28; Honolulu

61.

Greenhill L. Once-daily methylphenidate modified-release (methylphenidate MR) treatment of attention-deficit/hyperactivity disorder (ADHD): the Methylphenidate MR ADHD Study Group [poster presentation]. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2000 Oct 24–29; New York

62.

Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 109: E39PubMedCrossRef

63.

Lyseng-Williamson KA, Keating GM. Extended release methylphenidate (Ritalin® LA). Drugs 2002; 62(15): 2251–9PubMedCrossRef

64.

Silva R, Tilker H, Cecil J, et al. Open label, pilot study of dexmethylphenidate in children with ADHD [poster presentation]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2001 Oct 23–28; Honolulu

65.

Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 1999; 104: 1300–11PubMedCrossRef

66.

Swanson JM, Wigal SB, Greenhill L, et al. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry 1998; 37(5): 519–26PubMedCrossRef

67.

McCracken JT, Biederman J, Greenhill L, et al. Analog classroom assessment of SLI381 for treatment of ADHD [poster presentation]. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); 2000 Oct 24–29; New York

68.

Successful ADDERALL XR™ launch provides Shire with strong platform for mid to long term growth [press release]. Basingstoke: Shire Pharmaceuticals Group plc, 2002 May 1

69.

Bussing R, Gary FA. Practice guidelines and parental ADHD treatment evaluations: friends or foes? Harvard Rev Psychiatry 2001; 9(5): 223–33CrossRef

70.

Cohen NJ, Thompson L. Perceptions and attitudes of hyperactive children and their mothers regarding treatment with methylphenidate. Can J Psychiatry 1982; 27(1): 40–2PubMed

71.

Corkum P, Rimer P, Schachar R. Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrollment and adherence to a 12-month treatment trial. Can J Psychiatry 1999; 44(10): 1043–8PubMed

72.

Bennett DS, Power TJ, Rostain AL, et al. Parent acceptability and feasibility of ADHD interventions: assessment, correlates, and predictive validity. JPediatrPsychol 1996; 21(5): 643–57PubMedCrossRef

73.

Roberts KJ. Barriers to and facilitators of HIV-positive patients’ adherence to antiretroviral treatment regimens. AIDS Patient Care STDS 2000; 14(3): 155–68PubMedCrossRef

74.

Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients’ perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med 1998; 13(9): 586–93PubMedCrossRef

75.

Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 2002; 109 (6 Pt 2): 554S–9SCrossRef

76.

Odom SE. Effects of an educational intervention on mothers of male children with attention deficit hyperactivity disorder. J Community Health Nurs 1996; 13(4): 207–20PubMedCrossRef

77.

Greenfield BJ, Senecal J. Recreational multifamily therapy for troubled children. Am J Orthopsychiatry 1995; 65(3): 434–9PubMedCrossRef

78.

Anastopoulos AD, Shelton TL, DuPaul GJ, et al. Parent training for attention-deficit hyperactivity disorder: its impact on parent functioning. J Abnorm Child Psychol 1993; 21(5): 581–96PubMedCrossRef

Titel: Compliance with Stimulants for Attention-Deficit/Hyperactivity Disorder
Issues and Approaches for Improvement
verfasst von: Dr James Swanson
Publikationsdatum: 01.02.2003
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 2/2003
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200317020-00004

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2003

Stimulation of the Nervous System for the Management of Seizures

Pharmacological Treatment of Vertigo

Bupropion for the Treatment of Tobacco Dependence